Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome: Conceptual chances

NuklearMedizin

Volumn 44, Issue 3, 2005, Pages

  Buchmann, Inga ^a   Meyer, R G ^a   Herr, W ^a   Helisch, A ^a   Bartenstein, P ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Haematology; Leukaemia; Radioimmuntherapy; Transplantation

Indexed keywords

ACTINIUM; ANTIBODY CONJUGATE; CD33 ANTIGEN; CD45 ANTIGEN; IODINE 131; LUTETIUM; RHENIUM 186; RHENIUM 188; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; BETA RADIATION; CANCER CHEMOTHERAPY; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; RADIOIMMUNOTHERAPY; RELAPSE; REVIEW; SURVIVAL RATE; TOXICITY; TREATMENT FAILURE; TUMOR CELL; RECURRENT DISEASE; REPRODUCIBILITY;

HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; RADIOIMMUNOTHERAPY; RECURRENCE; REPRODUCIBILITY OF RESULTS;

EID: 20444481042     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625714     Document Type: Review

References (49)

1. Behr TM, Behe M, Lohr M et al. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000; 27: 753-65.
2. Bennet JM, Catovsky D, Daniel MT et al. French-American-British (FAB) co-operative group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
3. Boiron JM, Lerner D, Pigneux A et al. Allogeneic transplantation for patients with advanced acute leukemia: A single center retrospective study of 92 patients. Leuk Lymphoma 2001; 41: 285-96.
4. Buchholz HG, Herzog H, Forster GJ et al. PET imaging with yttrium-86: Comparisons of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003; 30: 716-20.
5. Buchmann I, Bunjes D, Kotzerke J et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-Antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation. Cancer Biother & Radiopharm 2002, 17: 151-63.
6. Buchmann I, Mutschler J, Steinbach G et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb before stem cell transplantation does not increase cytokine levels. J Nucl Med 2002; 43: S314P.
7. Buchmann I, Schulz A, Sparber M et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb in paediatric leukaemia patients: A phase I-trial. J Nucl Med 2002; 43: S37P.
8. 99mTc-anti-CD45-mAb YTH24.5 with regard to suitability for myeloablative radioimmunotherapy. Eur J Nucl Med Mol Imaging 2003; 30: 667-73.
9. Bunjes D, Buchmann I, Duncker C et al. Re-188-labeled anti-CD 66 (a,b,c,e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98: 565-72.
10. Bunjes D. Re-188-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leukemia & Lymphoma 2002; 43: 2125-31.
11. Caron PC, Co MS, Bull MK et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761-7.
12. Caron PC, Jurcic JG, Scott AM et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood 1994; 83: 1760-8.
13. Cassileth PA, Harrington DP, Applebaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Eng J Med 1998; 339: 1649-56.
14. Forrer F. Nuklearmedizin: Lu-177-DOTA-Rituximab. Schweiz Med Forum 2003; 51/52: 1266-8.
15. Geissler F, Anderson SK, Venkatesan P et al. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992; 52: 2907-15.
16. Glatting G, Kull T, Blumstein NM et al. Dosimetry with Re-188 labelled anti-CD66 antibodies: Does the measurement of a biodistribution 3 hp.i. suffice to predict the residence times? Eur J Nucl Med 2004; 31: S473.
17. Griffiths GL, Govidan SY Sgouros G et al. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999; 81: 985-92.
18. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
19. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1386-92.
20. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 8: 3204-13.
21. Hill GR, Krenger W, Ferrara JLM et al. Cytokine Dysregulation in acute graft-versus-host disease. Hem 1997; 2: 423-34.
22. Holler E, Kolb HJ, Mittermüller J et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 1995; 86: 890-9.
23. Jaffe ES, Harris NL, Stein H et al. World Health Classification of Tumours: Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARCPress, Lyon 2001.
24. Jowsey J, Rowland RE, Marshall JH. The deposition of the rare earths in bone. Radiation Res 1958; 8: 490-501.
25. Jurcic JG, Caron PC, Nikula TK et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55: S5908-10.
26. Jurcic JG, Divgi CCR, McDevitt MR et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 24.
27. Jurcic JG, Larson SM, Sgouros G et al. Targeted α-particle immunotherapy for myloid leukemia. Blood 2002; 100: 1233-9.
28. Kaminski MS, Zasadny, KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with I-131-anti-B1 (anti-CD20) antibody. N Engl J Nucl Med 1993; 329: 459-65.
29. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-66.
30. 188Re in a balloon catheter. Nucl Med Comm 1998; 19: 795-801.
31. Matthews DC, Appelbaum FR, Eary JF et al. Development of a marrow transplantation regimen for acute leukemia using targeted hematopoietic irradiation delivered by I-131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85: 1122-31.
32. Matthews DC. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia. 1998; 12: S33-6.
33. Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237-47.
34. Michel RB, Brechbiel MW, Mattes MJ. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 2003; 44: 632-40.
35. 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004; 45: 129-37.
36. Möllenbeck J, Schweickert H. Krebstherapie mit dem kurzlebigen Strahler Bi-213. Nachrichten - Forschungszentrum Karlsruhe 2000; 32: 87-90.
37. Newland A. Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol 2002; 76: S253-8.
38. Nikula TK, Bocchia M, Curcio MJ et al. Impact of the high tyrosine fraction in complemantarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 1995; 32: 865-72.
39. Postema EJ, Raemaekers JM, Oyen WJ et al. Final results of a phase I radioimmunotherapy trial using Re-186-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cane Res 2003; 9: S3995-4002.
40. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-40.
41. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Eng J Med 1998; 339: 605-15.
42. Reske SN, Bunjes D, Buchmann I et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med 2001; 28: 807-15.
43. Scheinberg DA, Tanimoto M, McKenzie S et al. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia 1989; 3: 440-5.
44. Schwartz MA, Lovett DR, Redner A et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294-303.
45. Sgouros G, Ballangrud AM, Jurcic JG et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999; 40: 1935-46.
46. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-46.
47. Shih LB, Thorpe SR, Griffiths GL et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med 1994; 35: 899-908.
48. Witherspoon RP, Deeg HJ, Storer B et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134-41.
49. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-803.